EP3788079A4 - Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci - Google Patents

Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci Download PDF

Info

Publication number
EP3788079A4
EP3788079A4 EP19796462.0A EP19796462A EP3788079A4 EP 3788079 A4 EP3788079 A4 EP 3788079A4 EP 19796462 A EP19796462 A EP 19796462A EP 3788079 A4 EP3788079 A4 EP 3788079A4
Authority
EP
European Patent Office
Prior art keywords
lag
high affinity
binding proteins
made therefrom
bispecific binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19796462.0A
Other languages
German (de)
English (en)
Other versions
EP3788079A1 (fr
Inventor
Xuan WU
Shiyong GONG
Chengbin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Epimab Biotherapeutics Co Ltd
Original Assignee
Shanghai Epimab Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Epimab Biotherapeutics Co Ltd filed Critical Shanghai Epimab Biotherapeutics Co Ltd
Publication of EP3788079A1 publication Critical patent/EP3788079A1/fr
Publication of EP3788079A4 publication Critical patent/EP3788079A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19796462.0A 2018-05-03 2019-04-30 Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci Pending EP3788079A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018085468 2018-05-03
PCT/CN2019/085164 WO2019210848A1 (fr) 2018-05-03 2019-04-30 Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci

Publications (2)

Publication Number Publication Date
EP3788079A1 EP3788079A1 (fr) 2021-03-10
EP3788079A4 true EP3788079A4 (fr) 2022-12-21

Family

ID=68386276

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19796462.0A Pending EP3788079A4 (fr) 2018-05-03 2019-04-30 Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci

Country Status (11)

Country Link
US (1) US20210188980A1 (fr)
EP (1) EP3788079A4 (fr)
JP (1) JP7368453B2 (fr)
KR (1) KR20210005894A (fr)
CN (1) CN112074541A (fr)
AU (1) AU2019263850A1 (fr)
BR (1) BR112020022371A2 (fr)
CA (1) CA3097916A1 (fr)
MX (1) MX2020011588A (fr)
TW (1) TWI784190B (fr)
WO (1) WO2019210848A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008667A (es) * 2013-12-30 2017-02-02 Epimab Biotherapeutics Inc Inmunoglobulina con fab en tandem y usos de esta.
CN114728065A (zh) * 2019-11-26 2022-07-08 上海岸迈生物科技有限公司 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN114907478A (zh) * 2021-02-08 2022-08-16 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
WO2022188801A1 (fr) * 2021-03-10 2022-09-15 北京拓界生物医药科技有限公司 Protéine de liaison à pd-1 et son utilisation pharmaceutique
US20220363761A1 (en) * 2021-03-31 2022-11-17 Merus N.V. Multispecific binding moieties comprising novel pd-1 binding domains
CN114989297B (zh) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 包含辣根过氧化物酶标记的抗体的试剂盒
WO2024072893A1 (fr) * 2022-09-28 2024-04-04 Incyte Corporation Anticorps bispécifiques dirigés contre pd-1/lag-3 et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017019846A1 (fr) * 2015-07-30 2017-02-02 Macrogenics, Inc. Molécules se liant à pd-1 et méthodes d'utilisation correspondantes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008667A (es) * 2013-12-30 2017-02-02 Epimab Biotherapeutics Inc Inmunoglobulina con fab en tandem y usos de esta.
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CR20160425A (es) * 2014-03-14 2017-05-26 Novartis Ag Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017024515A1 (fr) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Nouveaux anticorps anti-pd-1
CA3132021C (fr) * 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Liants de pd1 et/ou lag3
WO2017132827A1 (fr) * 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
ES2858091T3 (es) * 2016-06-20 2021-09-29 F Star Therapeutics Ltd Moléculas de unión que se unen a PD-L1 y LAG-3
CN114456269A (zh) * 2016-09-21 2022-05-10 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
EP3526255A2 (fr) * 2016-10-13 2019-08-21 Symphogen A/S Anticorps anti-lag-3 et compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017019846A1 (fr) * 2015-07-30 2017-02-02 Macrogenics, Inc. Molécules se liant à pd-1 et méthodes d'utilisation correspondantes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUESTA A M ET AL: "Multivalent antibodies: when design surpasses evolution", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 28, no. 7, 1 July 2010 (2010-07-01), pages 355 - 362, XP027102411, ISSN: 0167-7799, [retrieved on 20100504] *
DEYEV SERGEY M ET AL: "Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design", BIOESSAYS, JOHN WILEY & SONS LTD, GB, vol. 30, no. 9, 1 September 2008 (2008-09-01), pages 904 - 918, XP002663706, ISSN: 0265-9247, DOI: 10.1002/BIES.20805 *
JAIN ET AL: "Engineering antibodies for clinical applications", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 25, no. 7, 1 July 2007 (2007-07-01), pages 307 - 316, XP022116341, ISSN: 0167-7799 *
MATTHEW J BERNETT ET AL: "Multiple Bispecific Checkpoint Combinations Promote T cell activation I t d ti TIL h k i t t Negative Control PD-1 x LAG-3 Bispecific CTLA-4 / CD80 (nm) PD-1 / PD-L2 I) CTLA-4 / CD86 (nm) 0 2 0 3 BTLA / HVEM (nm) LAG-3 / MHC II I) g @BULLET CTLA-4 x LAG-3 bispecific combines productively with anti-P", 6 November 2016 (2016-11-06), XP055442869, Retrieved from the Internet <URL:http://files.shareholder.com/downloads/AMDA-2B2V8N/0x0x916283/67AE1A8B-40E8-4316-9F79-384D06B2C395/XNCR_SITC_2016_PD1xCTLA4_Poster126_12Nov2016.pdf> [retrieved on 20180122] *
RINSE KLOOSTER ET AL: "Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity (B088)", 23 September 2016 (2016-09-23), XP055442867, Retrieved from the Internet <URL:http://www.merus.nl/wordpress/wp-content/uploads/2015/10/Poster-ICIC-New-York-26Sep16-final.pdf> [retrieved on 20180122] *

Also Published As

Publication number Publication date
MX2020011588A (es) 2020-12-07
TW202041537A (zh) 2020-11-16
WO2019210848A1 (fr) 2019-11-07
TWI784190B (zh) 2022-11-21
BR112020022371A2 (pt) 2021-02-02
KR20210005894A (ko) 2021-01-15
CA3097916A1 (fr) 2019-11-07
AU2019263850A1 (en) 2020-11-19
EP3788079A1 (fr) 2021-03-10
JP7368453B2 (ja) 2023-10-24
JP2021522347A (ja) 2021-08-30
CN112074541A (zh) 2020-12-11
US20210188980A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EP3788079A4 (fr) Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci
EP3875485A4 (fr) Anticorps bispécifique se liant à cd20 et cd3 et utilisations associées
EP3720963A4 (fr) Molécule de liaison à l&#39;antigène comprenant une région variable d&#39;anticorps modifiée se liant à cd3 et cd137
IL268527A (en) Bispecific antibodies bind PD1 and LAG3 specifically
IL283939A (en) Antibodies bind to cd3
AU2016210068A1 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
EP4025602A4 (fr) Anticorps se liant à tslp et leurs utilisations
EP3856785A4 (fr) Molécules de liaison à l&#39;antigène capables de se lier à cd3 et cd137 mais pas simultanément
EP3816187A4 (fr) Anticorps monoclonal se liant de manière spécifique à lag-3 et son utilisation
EP4065164A4 (fr) Anticorps anti-cd3 et anti-bcma, et protéines de liaison bispécifiques fabriquées à partir de ceux-ci
SG11202108062PA (en) Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3
EP3604334A4 (fr) Anticorps se liant spécifiquement à muc1 et son utilisation
MX2019010999A (es) Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.
EP3998283A4 (fr) Anticorps se liant de manière spécifique à b7-h3 et son utilisation
EP3774917A4 (fr) Anticorps à domaine unique contre lag-3 et leurs utilisations
EP3902822A4 (fr) Protéines de liaison anti-pd-1 et méthodes d&#39;utilisation de celles-ci
EP3847196A4 (fr) Protéines de liaison à un antigène bispécifiques et leurs utilisations
EP3781202A4 (fr) Anticorps de liaison au pd-1 et leurs utilisations
EP3902821A4 (fr) Protéines de liaison anti-ctla-4 et méthodes d&#39;utilisation de celles-ci
EP3773716A4 (fr) Anticorps monoclonaux qui se lient à ssea4 et leurs utilisations
EP3768727A4 (fr) Nouvelles molécules d&#39;anticorps pd-1/lag-3 bispécifiques
EP3880245A4 (fr) Compositions et procédés pour l&#39;administration cytoplasmique d&#39;anticorps et d&#39;autres protéines
EP3931223A4 (fr) Anticorps se liant à pd-1
EP3904387A4 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l&#39;humain
EP3902840A4 (fr) Protéines multispécifiques de liaison à l&#39;antigène pouvant se lier à cd19 et cd3, et leur utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220715BHEP

Ipc: A61K 39/395 20060101ALI20220715BHEP

Ipc: C12N 5/10 20060101ALI20220715BHEP

Ipc: C07K 16/28 20060101AFI20220715BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220804BHEP

Ipc: A61K 39/395 20060101ALI20220804BHEP

Ipc: C12N 5/10 20060101ALI20220804BHEP

Ipc: C07K 16/28 20060101AFI20220804BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20221117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20221111BHEP

Ipc: A61K 39/395 20060101ALI20221111BHEP

Ipc: C12N 5/10 20060101ALI20221111BHEP

Ipc: C07K 16/28 20060101AFI20221111BHEP